Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

By G. Abou-Alfa, Lawrence H. Schwartz, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Grève, J. Douillard, C. Lathia, B. Schwartz and 3 more. Journal of Clinical Oncology, 2006

1,204 citations recorded by the source corpus.

Subfields: Hepatology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/9d60f52271bc11d668103d0ae2379f746143b01d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. Riccardo Lencioni
4. V. Mazzaferro
5. L. Kulik
6. Andrew X. Zhu
7. Peter R. Galle
8. T. de Baère

In Molecular Biology

1. D. Tang
2. R. Kang
3. Jordi Bruix1 , 2
4. F. McCormick
5. Xiaofang Sun
6. M. Ferracin
7. M. Negrini
8. Brent R. Stockwell

Citations in the corpus

• MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma (2008, background): “Oral multikinase inhibitors, in particular, have been recently tested in patients with nonsurgical HCC providing the evidence of a moderate efficacy and a manageable toxicity (Abou-Alfa et al., 2006; Llovet et al., 2007).”
• Activation of the p62-Keap1-NRF2 Pathway Protects against Ferroptosis in Hepatocellular Carcinoma Cells (2015, background): “Sorafenib, a multiple kinase inhibitor, is the first systemic therapy to improve survival in HCC and is now a standard treatment pending approval by the US Food and Drug Administration for patients with unresectable HCC.2,3 However, sorafenib has been shown to provide limited survival benefits, sugg”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Following an initial phase II study showing a signal of efficacy [322], a large double-blinded placebo controlled phase III investigation was conducted, leading to positive survival results [168].”
• Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling (2008, background): “001) suggests that high baseline pERK levels may predict response to sorafenib (64).”
• Dragging ras back in the ring. (2014, background): “In hepatocellular carcinoma, biomarker analysis in Phase II clinical trials showed a clear correlation between levels of phosphoERK and clinical response, suggesting that inhibition of Raf kinase is responsible for part of the clinical benefit (Abou-Alfa et al., 2006), but in the other indications, ”
• Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010, background): “5) 7 (15) Child–Pugh B 35 (34) 23 (68) 18 (53) 17.”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “Following an initial phase II study showing a signal of efficacy [322], a large double-blinded placebo controlled phase III investigation was conducted, leading to positive survival results [168].”
• Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “46 days in those without activation of the pathway [115].”